Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: A comparison analysis

Clinical Lung Cancer

Volumn 15, Issue 4, 2014, Pages 307-312

  Passaro, Antonio ^a   Di Maio, Massimo ^b   Del Signore, Ester ^a   Gori, Bruno ^c   De Marinis, Filippo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Oncological Pulmonary 1st Unit   (Italy)

Author keywords

Afatinib; Diarrhea; Erlotinib; Gefitinib; Skin rash

Indexed keywords

AFATINIB; ERLOTINIB; GEFITINIB; ANTIINFECTIVE AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; SCORING SYSTEM; STOMATITIS; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; EXANTHEMA; FEEDING BEHAVIOR; INCIDENCE; LUNG NEOPLASMS; METASTASIS; MUCOSITIS; TREATMENT WITHDRAWAL;

ANTI-BACTERIAL AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; EXANTHEMA; FOOD HABITS; HUMANS; INCIDENCE; LUNG NEOPLASMS; MUCOSITIS; NEOPLASM METASTASIS; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; WITHHOLDING TREATMENT;

EID: 84903145666     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.04.006     Document Type: Article

References (19)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. A.G. Pallis, and K.N. Syrigos Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC Lung Cancer 80 2013 120 130
3. N.T. Tanner, N.J. Pastis, and C. Sherman et al. The role of molecular analyses in the era of personalized therapy for advanced NSCLC Lung Cancer 76 2012 131 137
4. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
5. R. Rosell, E. Carcereny, and R. Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
6. C. Zhou, Y.L. Wu, and G. Chen et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
7. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
8. A. Inoue, K. Kobayashi, and M. Maemondo et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations J Clin Oncol 29 2011 7519
9. J.Y. Han, K. Park, and S.W. Kim et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 30 2012 1122 1128
10. T. Mitsudomi, S. Morita, and Y. Yatabe et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2012 121 128
11. L.V. Sequist, J.C. Yang, and N. Yamamoto et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3327 3334
12. J.C. Yang, V. Hirsh, and M. Schuler et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3342 3350
13. V.A. Miller, V. Hirsh, and J. Cadranel et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol 13 2012 528 538
14. LUX-Lung 5: afatinib plus weekly paclitaxel versus investigator's choice of single agent chemotherapy following afatinib monotherapy in non-small cell lung cancer patients failing erlotinib or gefitinib. Available at: http://clinicaltrials.gov/show/NCT01085136.
15. M.E. Lacouture, D. Schadendorf, and C.Y. Chu et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker Expert Rev Anticancer Ther 13 2013 721 728
16. J.C. Yang, N. Reguart, and J. Barinoff et al. Diarrhea associated with afatinib: an oral ErbB family blocker Expert Rev Anticancer Ther 13 2013 729 736
17. L.S. Elting, C. Cooksley, and M. Chambers et al. The burden of cancer therapy: clinical and economic outcomes of chemotherapy induced mucositis Cancer 98 2003 1531 1539
18. D.E. Peterson, R.J. Bensadoun, F. Roila ESMO Guidelines Working Group Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines Ann Oncol 22 suppl 6 2011 vi78 vi84
19. R.J. Gibson, D.M. Keefe, and R.V. Lalla et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients Support Care Cancer 21 2013 313 326